课题基金 / 基金详情

Integrative Analyses of Saturation CRISPR Protein Scan

Integrative Analyses of Saturation CRISPR Protein Scan
饱和 CRISPR 蛋白质扫描的综合分析
批准号:
10058930
负责人:
Chun-Wei David Chen
金额:
$13.2万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2022-03-31

项目摘要

项目成果

Chun-Wei David Chen的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Epigenetic mechanisms play a critical role in controlling gene expression during normal development and are often altered in disease states, particularly in cancer. MLL-rearranged (MLL-r) leukemias account for 5-10% of human acute leukemia and is associated with poor prognosis. The unmet clinical needs and the lack of effective targeted therapy to the MLL-r leukemias emphasize the need for novel regimens. Recent cancer epigenetics studies discovered a central role for the histone H3 lysine 79 (H3K79) methyltransferase DOT1L in MLL-r leukemogenesis. Important clinical responses have been noted with DOT1L inhibitor treatment as a single agent, however, it is expected that combination treatments will be necessary. Our preliminary studies proposed in the parent award R01 CA236626 based on a high-density CRISPR genetic screen of DOT1L have identified the potential of “saturation CRISPR protein scan” in de novo functional domain discovery. The objective of this Revision Application is to establish a computational pipeline to facilitate the data analyses of the saturation CRISPR protein scan. Our central hypothesis is that saturation CRISPR protein scan data harbor clinically impactful information that can be further explored through adaptation of the integrative informatics tools from the ITCR Program. We will (Aim 1) integrate the saturation CRISPR protein scan with cBioPortal (an integrative clinical genomic database; funded by ITCR) to identify clinically relevant alleles, and (Aim 2) streamline the saturation CRISPR protein scan with DINC 2.0 (a parallelized meta- docking method for the incremental docking of large ligands; funded by ITCR) to identify lead epigenetic ligands to the CRISPR defined hotspots. This study is innovative because (1) it introduces a novel concept of using saturation CRISPR genetic screens for epigenetic ligand discovery, and (2) it establishes an analysis pipeline for a novel field that bridges the functional genomics, protein domain identification, and therapeutics discovery. The impact of this research will be of significance because (1) it immediately provides novel therapeutic opportunities against the difficult-to-treat MLL-r leukemias, and (2) the computational pipeline established in this proposal and streamlined with the ITCR supported integrative informatics tools will help identify novel functional elements for future pharmaceutical targeting in multiple types of cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism and therapeutic opportunities of targeting the Tudor domain
Role of BAZ2A in MLL-r leukemia and therapeutic response
Role of BAZ2A in MLL-r leukemia and therapeutic response
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia